NCT03940703 2026-02-27A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)EMD SeronoPhase 2 Active not recruiting140 enrolled 47 charts
NCT02864992 2025-12-23Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)EMD SeronoPhase 2 Active not recruiting337 enrolled 13 charts 2 FDA
NCT03492437 2023-08-07Effect of Tepotinib on the PK of the P-gp Substrate Dabigatran EtexilateMerck KGaA, Darmstadt, GermanyPhase 1 Completed20 enrolled 14 charts